Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 3.45Procter & Gamble Health Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strengths in solvency and efficiency, particularly in managing inventory and receivables. However, it faces significant challenges in liquidity, growth, coverage, profitability, and key financial metrics such as earnings per share and margins. Capital expenditure management appears to be a notable positive aspect. The company's overall financial health suggests a need for improvement in several areas to ensure sustainable growth and stability. While it effectively handles some operational aspects, addressing weaknesses in profitability and liquidity will be crucial for future success.
Health Score : 3.45Procter & Gamble Health Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company demonstrates strengths in solvency and efficiency, particularly in managing inventory and receivables. However, it faces significant challenges in liquidity, growth, coverage, profitability, and key financial metrics such as earnings per share and margins. Capital expenditure management appears to be a notable positive aspect. The company's overall financial health suggests a need for improvement in several areas to ensure sustainable growth and stability. While it effectively handles some operational aspects, addressing weaknesses in profitability and liquidity will be crucial for future success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
26.87
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
29.33
P/B RATIO
18.28
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
N/A
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
0.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹5776 as on Sep 1, 2026.
Growth Score : 2.00The growth performance is weak across all metrics, indicating limited expansion and potential stagnation. This could stem from market saturation, competitive pressures, or ineffective growth strategies. The company may face challenges in attracting investors and maintaining market share. Focus on innovation and strategic investments is crucial to revitalize growth prospects and ensure long-term sustainability. The company needs to improve its growth prospects.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoor| Growth Ratios | Jun 2024 | Mar 2026 |
|---|---|---|
| Revenue Growth Rate | -6.42 | 50.75 |
| Operating Profit Growth Rate | -5.54 | 43.89 |
| Earnings Per Share (EPS) Growth | -12.41 | 39.46 |
| Asset Growth Rate | -27.88 | |
| Net Income Growth Rate | -12.23 | 39.74 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 9 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 10 | Shilpa Medicare Ltd | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 14 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 15 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 16 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 17 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 18 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Procter & Gamble Health Ltd (PGHL) is a leading Indian healthcare company, part of the global P&G family. It specializes in manufacturing and marketing over-the-counter (OTC) products, vitamins, minerals, and supplements (VMS). PGHL boasts a strong portfolio of trusted brands across therapeutic and nutraceutical segments, establishing itself as a key player in the wellness market.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Procter & Gamble Health Ltd's P/E ratio (TTM) is 26.87, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Procter & Gamble Health Ltd's P/B ratio is 18.28, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Procter & Gamble Health Ltd's P/S ratio is 7.40, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Procter & Gamble Health Ltd's PEG ratio is 1.14.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Procter & Gamble Health Ltd's EV/EBITDA ratio is 21.05.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Procter & Gamble Health Ltd's ROE is 62.29%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Procter & Gamble Health Ltd's ROA is 54.58%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Procter & Gamble Health Ltd's ROCE is 84%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Procter & Gamble Health Ltd's operating margin is 32.60%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Procter & Gamble Health Ltd's net margin is 23.22%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Procter & Gamble Health Ltd's current ratio is 2.36.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Procter & Gamble Health Ltd's debt-to-equity ratio is 0.02.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Procter & Gamble Health Ltd's interest coverage ratio is 451.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Procter & Gamble Health Ltd's DPS is ₹204.82.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Procter & Gamble Health Ltd's EPS is 39.46.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹5776. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1967 (as E. Merck (India) Private Limited) (as Merck Limited)
Headquarters: Mumbai, Maharashtra
Core Offerings: Over-the-counter (OTC) medicines, Vitamins, Minerals, Nutritional supplements, Digestive remedies
Stock Listing: NSE (PGHL), BSE (500126)
Promoter: The Procter & Gamble Company / Procter & Gamble Overseas N.V.
1967: Incorporated as E. Merck (India) Private Limited. 1981: Converted to a public limited company, E. Merck (India) Ltd. 2018: Following the global acquisition of Merck KGaA's consumer health business by Procter & Gamble, the Indian entity was renamed Procter & Gamble Health Limited. It continues its focus on over-the-counter (OTC) and nutraceutical products in India.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Healthcare Products (Pharmaceuticals, OTC, VMS) | Major Portion | N/A (not reported separately) |
Healthcare Products: Focuses on manufacturing and marketing a comprehensive range of over-the-counter (OTC) products, vitamins, minerals, and supplements (VMS), along with select prescription products.
Therapeutic Areas: Key therapeutic areas include Vitamins, Minerals, and Supplements (VMS), Digestive Health, Cough & Cold, and Women's Health, catering to various consumer health needs.
Brands: The company manages a strong portfolio of iconic brands such as Neurobion, Livogen, SevenSeas, Nasivion, Polybion, and Evion, which are market leaders in their respective categories.
Operations: Utilizes a mix of in-house manufacturing capabilities and contract manufacturing partnerships to ensure efficient production and supply chain management for its diverse product range.
Mr. L. V. Ravishankar - Managing Director: An experienced leader with a strong track record in the FMCG and healthcare sectors, steering the company's strategic growth and operational excellence. Mr. G. N. S. Madhavan - Chairman (Non-Executive Director): A seasoned professional contributing strategic oversight and governance to the board.
No major subsidiaries reported.
2018: Global acquisition of Merck KGaA's consumer health business by Procter & Gamble led to the renaming of the Indian entity from Merck Limited to Procter & Gamble Health Limited, significantly integrating it into the P&G global portfolio.
The Procter & Gamble Health Ltd share price today is ₹5776 on NSE (PGHL), as of 26 Sept 2026.
As of 25 Sept 2026, Procter & Gamble Health Ltd share price is ₹5776, with previous close ₹5776. Today's range is ₹5776 to ₹5776. The 52-week range is ₹4707 to ₹6975.
As of today, Procter & Gamble Health Ltd's market cap is ₹0 crore (Small Cap).
Procter & Gamble Health Ltd's current P/E ratio is 26.87, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 36.50.
Procter & Gamble Health Ltd's current P/B ratio is 18.28.
Procter & Gamble Health Ltd's current dividend yield is 3.55%. Last dividend of ₹36.00 per share was declared on 26-Jul-2024.
Procter & Gamble Health Ltd's EPS (TTM) is ₹39.46.
Procter & Gamble Health Ltd (PGHL) is a leading Indian healthcare company, part of the global P&G family. It specializes in manufacturing and marketing over-the-counter (OTC) products, vitamins, minerals, and supplements (VMS). PGHL boasts a strong portfolio of trusted brands across therapeutic and nutraceutical segments, establishing itself as a key player in the wellness market.
Procter & Gamble Health Ltd is promoted by The Procter & Gamble Company / Procter & Gamble Overseas N.V., holding 51.82% as of 25 Sept 2026.
Procter & Gamble Health Ltd is listed on NSE (PGHL) and BSE (500126). Its next quarterly results are expected on Oct/Nov 2024 (Q2 FY25).
Capital Expenditures (CapEx)
Financial Performance & Growth
